Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation.

[1]  D. Piomelli,et al.  The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-α Mediates the Anti-Inflammatory Actions of Palmitoylethanolamide , 2005, Molecular Pharmacology.

[2]  N. Kaminski,et al.  A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes , 2004, Journal of Pharmacology and Experimental Therapeutics.

[3]  D. Piomelli,et al.  Oleoylethanolamide Stimulates Lipolysis by Activating the Nuclear Receptor Peroxisome Proliferator-activated Receptor α (PPAR-α)* , 2004, Journal of Biological Chemistry.

[4]  T. Willson,et al.  Polyunsaturated Fatty Acids Including Docosahexaenoic and Arachidonic Acid Bind to the Retinoid X Receptor α Ligand-binding Domain* , 2004, Molecular & Cellular Proteomics.

[5]  K. Saeki,et al.  Lipid droplet formation in human myeloid NB4 cells stimulated by all trans retinoic acid and granulocyte colony-stimulating factor: possible involvement of peroxisome proliferator-activated receptor gamma. , 2003, Cell structure and function.

[6]  S. Gaetani,et al.  Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α , 2003, Nature.

[7]  I. Maruyama,et al.  Anandamide induces cell death independently of cannabinoid receptors or vanilloid receptor 1: possible involvement of lipid rafts , 2003, Cellular and Molecular Life Sciences CMLS.

[8]  H. Lodish,et al.  Troglitazone Antagonizes Tumor Necrosis Factor-α-induced Reprogramming of Adipocyte Gene Expression by Inhibiting the Transcriptional Regulatory Functions of NF-κB* , 2003, Journal of Biological Chemistry.

[9]  Hui Li,et al.  Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. , 2003, Molecular pharmacology.

[10]  G. Appendino,et al.  Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway. , 2003, Molecular pharmacology.

[11]  Rajnish A. Gupta,et al.  15-Lipoxygenase Metabolism of 2-Arachidonylglycerol , 2002, The Journal of Biological Chemistry.

[12]  T. Willson,et al.  Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. , 2002, Biochemistry.

[13]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization. , 2002, Endocrinology.

[14]  P. Lory,et al.  Direct inhibition of T‐type calcium channels by the endogenous cannabinoid anandamide , 2001, The EMBO journal.

[15]  Z. Dong,et al.  Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. , 2001, The Biochemical journal.

[16]  J. Auwerx,et al.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. , 2001, Molecular cell.

[17]  S. Farmer,et al.  A Role for C/EBPβ in Regulating Peroxisome Proliferator-activated Receptor γ Activity during Adipogenesis in 3T3-L1 Preadipocytes* , 2001, The Journal of Biological Chemistry.

[18]  D. Deutsch,et al.  The Cellular Uptake of Anandamide Is Coupled to Its Breakdown by Fatty-acid Amide Hydrolase* , 2001, The Journal of Biological Chemistry.

[19]  M. Lazdunski,et al.  The endocannabinoid anandamide is a direct and selective blocker of the background K+ channel TASK‐1 , 2001, The EMBO journal.

[20]  C. Breivogel,et al.  Levels, Metabolism, and Pharmacological Activity of Anandamide in CB1 Cannabinoid Receptor Knockout Mice , 2000 .

[21]  T. Bisogno,et al.  Endocannabinoids: new targets for drug development. , 2000, Current pharmaceutical design.

[22]  B. Yagen,et al.  Oxidative metabolism of anandamide. , 2000, Prostaglandins & other lipid mediators.

[23]  Z. Dong,et al.  Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. , 2000, The Biochemical journal.

[24]  J. Chambers,et al.  The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) , 2000, British journal of pharmacology.

[25]  W. Wahli,et al.  Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.

[26]  L. Petrocellis,et al.  Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. , 1999, Current medicinal chemistry.

[27]  D. Julius,et al.  Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide , 1999, Nature.

[28]  T. Willson,et al.  Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase , 1999, Nature.

[29]  P. Casellas,et al.  Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. , 1999, The Journal of biological chemistry.

[30]  J. Winer,et al.  Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. , 1999, Analytical biochemistry.

[31]  L. Jendeberg,et al.  Crystal Structure of the Ligand Binding Domain of the Human Nuclear Receptor PPARγ* , 1998, The Journal of Biological Chemistry.

[32]  C. Ramesha,et al.  Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2* , 1997, The Journal of Biological Chemistry.

[33]  V. Lagente,et al.  Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. , 1997, European journal of pharmacology.

[34]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[35]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[36]  Kai Yu,et al.  Differential Activation of Peroxisome Proliferator-activated Receptors by Eicosanoids (*) , 1995, The Journal of Biological Chemistry.

[37]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[38]  J. Schwartz,et al.  Formation and inactivation of endogenous cannabinoid anandamide in central neurons , 1994, Nature.

[39]  D. Gibson,et al.  Isolation and structure of a brain constituent that binds to the cannabinoid receptor. , 1992, Science.

[40]  S. Wesselborg,et al.  Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses. , 2003, Critical reviews in immunology.

[41]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.